Apricus Biosciences Company Profile (NASDAQ:APRI)

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $2.32 (621.93% upside)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetActions
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Ascendiant Capital MarketsInitiated CoverageBuy$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2014Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Apricus Biosciences (NASDAQ:APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.09)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.13)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.10)($0.13)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q4($0.12)($0.09)$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.10)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.04)$0.05$5.45 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.09)($0.08)($0.09)
Q2 20162($0.10)($0.06)($0.08)
Q3 20162($0.08)($0.07)($0.08)
Q4 20162($0.05)($0.03)($0.04)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
DateHeadline
07/27/16 10:48 AMApricus Biosciences (APRI) Receives Approval for Vitaros in Lebanon - StreetInsider.com
07/27/16 10:48 AMApricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon - GlobeNewswire (press release)
07/27/16 06:18 AMApricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon - [at noodls] - SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic ...
07/26/16 08:09 PMApricus Biosciences (APRI) Announces Expansion of Vitaros Partnership
07/26/16 08:09 PMBRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals
07/26/16 08:09 PMApricus Biosciences Terminates One Agreement, Signs Another
07/25/16 07:21 AMBRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals - Reuters
07/25/16 07:21 AMApricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring ... - Nasdaq
07/25/16 06:28 AMApricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia - [at noodls] - Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate License Agreement ...
07/25/16 06:06 AMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events -
07/25/16 06:04 AM7:04 am Apricus Biosciences expands distribution agreement with Ferring Pharma for the commercialization of Vitaros, Novartis (NVS) unit Sandoz and Apricus agree to mutually terminate license agreement -
07/25/16 06:03 AMApricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia - [GlobeNewswire] - Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate License Agreement ...
07/22/16 07:33 PMAre Analysts Bearish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week? - Consumer Eagle
07/22/16 10:44 AMEarnings Focus and Crowd Sourced Sentiment Review for Apricus Biosciences, Inc (NASDAQ:APRI) - TGP
07/21/16 08:06 PMNew Market Report: Apricus Biosciences, Inc. (APRI) - Financial and Strategic SWOT Analysis Review
07/21/16 12:46 PMETF’s with exposure to Apricus Biosciences, Inc. : July 21, 2016 -
07/19/16 02:32 PMApricus Biosciences, Inc (NASDAQ:APRI) Expected To Post Sales Of $11.92 - Investor Newswire
07/19/16 02:32 PMApricus Biosciences Incorporated (NASDAQ:APRI) Short Interest Increased By 2.33% - Consumer Eagle
07/18/16 07:25 AMApricus Biosciences Incorporated (NASDAQ:APRI) Sellers Covered 5.82% of Their Shorts - Press Telegraph
07/17/16 02:29 PMNext Weeks Broker Price Targets For Apricus Biosciences, Inc (APRI) - Fiscal Standard
07/17/16 07:16 AMShares Moving Down on the Week: Apricus Biosciences, Inc. (NASDAQ:APRI) - Engelwood Daily
07/16/16 10:34 AMCrowd Rating and Earnings Recap for Apricus Biosciences, Inc (NASDAQ:APRI) - Telanagana Press
07/16/16 10:34 AMHC Stocks Assessment: Pfizer Inc. (NYSE:PFE), Apricus Biosciences Inc (NASDAQ:APRI) - share market updates (press release)
07/16/16 10:34 AMApricus Biosciences Inc (APRI): Price Target and June Short Interest Disclosure - Trade Calls
07/14/16 11:26 AMApricus Biosciences, Inc (NASDAQ:APRI) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 02:34 PMApricus Biosciences, Inc (APRI) Updated Price Targets - FTSE News
07/13/16 02:34 PMSentiment Report: Apricus Biosciences Inc (NASDAQ:APRI) - Press Telegraph
07/12/16 06:28 AMApricus Biosciences, Inc (NASDAQ:APRI) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 06:28 AMTrading Performance and Target Watch for Apricus Biosciences, Inc (NASDAQ:APRI) - Press Telegraph
07/09/16 10:36 AMApricus Biosciences Incorporated (NASDAQ:APRI) Shorts Decreased by 5.82% After Short Covering - Press Telegraph
07/08/16 02:33 PMWall Street Ratings and Target Price Views on Apricus Biosciences, Inc (NASDAQ:APRI) - Telanagana Press
07/08/16 02:33 PMWere Analysts Bearish Apricus Biosciences Inc (NASDAQ:APRI) This Week? - Press Telegraph
07/08/16 02:33 PMHC Stocks Alerts: Pfizer Inc. (NYSE:PFE), Apricus Biosciences Inc (NASDAQ:APRI) - share market updates (press release)
07/07/16 02:33 PMApricus Biosciences, Inc (NASDAQ:APRI) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 04:10 PMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K/A, Termination of a Material Definitive Agreement -
07/06/16 07:21 AMStock Rating Watch and Earnings Insight for Apricus Biosciences, Inc (NASDAQ:APRI) - Press Telegraph
07/06/16 07:01 AMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D -
07/06/16 07:00 AMApricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital - [GlobeNewswire] - SAN DIEGO, July 06, 2016-- Apricus Biosciences, Inc., a biopharmaceutical company focusing on the development and commercialization of novel therapeutics to treat areas of unmet medical need, today announced ...
07/05/16 07:19 AMSales of $11.92 expected for Apricus Biosciences, Inc (NASDAQ:APRI) - Investor Newswire
07/04/16 02:31 PMApricus Biosciences Incorporated (NASDAQ:APRI) Short Interest Decreased By 5.82% - Press Telegraph
07/03/16 07:19 AMCompany Stock Lower on the Week Apricus Biosciences, Inc. (NASDAQ:APRI) - Engelwood Daily
07/02/16 02:35 PMSell-Side Recommendation & Price Target Projections on Apricus Biosciences, Inc (NASDAQ:APRI) - Telanagana Press
07/01/16 04:52 PMETF’s with exposure to Apricus Biosciences, Inc. : July 1, 2016 -
06/30/16 02:39 PMApricus Biosciences, Inc (NASDAQ:APRI) Company Rating and Target Watch - Telanagana Press
06/29/16 07:41 PMShare Update and Earnings Review for Apricus Biosciences, Inc (NASDAQ:APRI) - Press Telegraph
06/29/16 10:46 AMRecently Issued Stock Ratings For Apricus Biosciences, Inc (APRI) - Fiscal Standard
06/28/16 07:55 PMBroker Outlook For The Week Ahead Apricus Biosciences, Inc (APRI) - Fiscal Standard
06/28/16 07:46 AMApricus Biosciences, Inc (NASDAQ:APRI) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 07:46 AMApricus Biosciences, Inc (NASDAQ:APRI) Yearly Sales Target At $11.92 - Investor Newswire
06/24/16 08:36 AMAre Analysts Bearish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week? - Press Telegraph

Social

About Apricus Biosciences

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Company's other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Company's permeation enhancer for the treatment of Raynaud's phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APRI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.32
  • 50 Day Moving Average: $0.3851
  • 200 Day Moving Average: $0.7020
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $19.17M
  • Beta: 0.63
  • Current Year EPS Consensus Estimate: $-0.17 EPS
Additional Links:
Apricus Biosciences (NASDAQ:APRI) Chart for Friday, July, 29, 2016